Myocarditis rates based on a single center (Massachusetts General Hospital) are 1.14% for all immune checkpoint inhibitors, 0.5% of patients on anti-PD1 alone, and 2.4% with combined anti-PD1/anti-CTLA4 antibodies.150. This evidence concerns the gene CTLA4 and myocarditis.